Other
Octreotide
Also called Sandostatin, SMS 201-995
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in the US and EU.
Quick start
Octreotide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 50–500 mcg per administration
- How often
- Twice a day
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Time to steady level
- ~9 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Octreotide describe 50–500 mcg per administration. Descriptive only, not a recommendation.
About 1.7 h for the immediate-release form; the monthly depot is a separate formulation with its own kinetics.
Octreotide (SMS 201-995), a synthetic somatostatin analog, licensed as a medicine in the US and EU. The immediate-release form is given subcutaneously about three times a day at 50–500 mcg; a separate long-acting depot is injected intramuscularly once a month and its figures do not carry over to this curve. The nearest standing frequency in the model is twice daily, so the three-times-daily schedule is stated in the table. Kvols (NEJM 1986) reported subcutaneous dosing in carcinoid syndrome research.
Dosing schedule
How Octreotide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Immediate-releaseThe short-acting form; a monthly intramuscular depot is a separate formulation. | 50–500 mcg | Three times daily | SubQ |
Modelled level — twice a day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 9hours
- Administrations
- 14/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Kvols LK et al., NEJM 1986;315:663A long-acting somatostatin analogue evaluated in malignant carcinoid syndrome; subcutaneous dosing measured symptom scores and circulating hormone markers.